Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05255393 · ClinicalTrials.gov registry record
Survey on Lymphedema After Sentinel Lymph Node Biopsy in People With Cervical or Vulvar Cancer
A clinical trial of Cervical Cancer and Vulvar Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 111
- Enrollment target
- 1
- Study location
NCT05255393: Completed study of Cervical Cancer and Vulvar Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05255393 is a study of Cervical Cancer and Vulvar Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 111 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05255393, a study of Cervical Cancer and Vulvar Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 111 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect information that may identify people who are at risk of developing lower extremity lymphedema (LEL) after sentinel lymph node biopsy (SLN) during surgery for early-stage vulvar or cervical cancer, and to improve the quality and accuracy of the information that is given to people who have this procedure. Please note that, during this study, the researchers will collect information from a questionnaire completed by people who had SLN and LND+/- SLN during surgery for early-stage cervical or vulvar cancer. No form of treatment will be provided as part of the study, and no investigational tests or procedures will be performed.
Primary Outcome
Prevalence will be measured using the 13-item questionnaire as reported by the patient.
Conditions Studied
Interventions
- OTHER Questionnaires
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2025-11-19 |
What the finished NCT05255393 record still lists
NCT05255393 is an observational study that tracks outcomes without assigning an intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which Questionnaires is the first listed.
NCT05255393 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05255393 about?
NCT05255393 is a clinical study titled "Survey on Lymphedema After Sentinel Lymph Node Biopsy in People With Cervical or Vulvar Cancer". The purpose of this study is to collect information that may identify people who are at risk of developing lower extremity lymphedema (LEL) after sentinel lymph node biopsy (SLN) during surgery for early-stage vulvar or cervical cancer, and to improve the quality and accuracy of the information that...
What is the current status of trial NCT05255393?
This trial is currently completed. The enrollment target is 111 participants. The study started on 2022-02-15. Estimated completion is 2025-11-19.
What conditions does trial NCT05255393 study?
This clinical trial studies the following conditions: Cervical Cancer, Vulvar Cancer.
What interventions are being tested in trial NCT05255393?
The interventions under investigation include: Questionnaires (OTHER).
Who is sponsoring clinical trial NCT05255393?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05255393 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05255393's enrollment target sits among peer trials
111 66th of 144 higher than 78 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Biological Drivers of Cervical Cancer and Side Effects From Radiation Therapy
RECRUITING
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
PopSci CHW4CervixHealth
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI